Human experimental endotoxemia in modeling the pathophysiology, genomics, and therapeutics of innate immunity in complex cardiometabolic diseases

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 35, Issue 3, 2015, Pages 525-534

  Patel, Parth N ^a   Shah, Rhia Y ^a   Ferguson, Jane F ^b   Reilly, Muredach P ^a,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Diabetes Research Center   (United States)

Author keywords

Chemotactic; Cytokines; Immune system; Inflammation; Metabolic syndrome X

Indexed keywords

ESCHERICHIA COLI ENDOTOXIN; GLUCOSE; LIPOPROTEIN; AUTACOID; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL; LIPID;

CARDIOVASCULAR DISEASE; EXPERIMENTAL ENDOTOXEMIA; GENOMICS; GLUCOSE METABOLISM; HUMAN; INFLAMMATION; INNATE IMMUNITY; METABOLIC DISORDER; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; REVIEW; ANIMAL; BLOOD; ENDOTOXEMIA; ESCHERICHIA COLI; GENETICS; GLUCOSE BLOOD LEVEL; HUMAN EXPERIMENT; IMMUNOLOGY; METABOLIC SYNDROME X; METABOLISM; MICROBIOLOGY; NORMAL HUMAN; PATHOGENICITY; PROCEDURES; PROGNOSIS;

ANIMALS; BIOMARKERS; BLOOD GLUCOSE; ENDOTOXEMIA; ESCHERICHIA COLI; GENOMICS; HEALTHY VOLUNTEERS; HUMAN EXPERIMENTATION; HUMANS; IMMUNITY, INNATE; INFLAMMATION; INFLAMMATION MEDIATORS; LIPIDS; METABOLIC SYNDROME X; PROGNOSIS;

EID: 84920396283     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.114.304455     Document Type: Review

References (139)

1. Hoffmann JA, Kafatos FC, Janeway CA, Ezekowitz RA. Phylogenetic perspectives in innate immunity. Science. 1999;284:1313-1318.
2. Medzhitov R, Janeway C Jr. Innate immunity. N Engl J Med. 2000;343:338-344. doi: 10.1056/NEJM200008033430506.
3. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. 2006;124:783-801. doi: 10.1016/j.cell.2006.02.015.
4. Pickup JC. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care. 2004;27:813-823.
5. Takeda K, Akira S. Toll-like receptors in innate immunity. Int Immunol. 2005;17:1-14. doi: 10.1093/intimm/dxh186.
6. Moresco EM, LaVine D, Beutler B. Toll-like receptors. Curr Biol. 2011;21:R488-R493. doi: 10.1016/j.cub.2011.05.039.
7. Parker LC, Prince LR, Sabroe I. Translational mini-review series on Tolllike receptors: networks regulated by Toll-like receptors mediate innate and adaptive immunity. Clin Exp Immunol. 2007;147:199-207. doi: 10.1111/j.1365-2249.2006.03203.x.
8. Wong ET, Tergaonkar V. Roles of NF-kappaB in health and disease: mechanisms and therapeutic potential. Clin Sci (Lond). 2009;116:451-465. doi: 10.1042/CS20080502.
9. Andreasen AS, Krabbe KS, Krogh-Madsen R, Taudorf S, Pedersen BK, Møller K. Human endotoxemia as a model of systemic inflammation. Curr Med Chem. 2008;15:1697-1705.
10. Sherwood ER, Toliver-Kinsky T. Mechanisms of the inflammatory response. Best Pract Res Clin Anaesthesiol. 2004;18:385-405.
11. Ulevitch RJ, Tobias PS. Receptor-dependent mechanisms of cell stimulation by bacterial endotoxin. Annu Rev Immunol. 1995;13:437-457. doi: 10.1146/annurev.iy.13.040195.002253.
12. Ferwerda B, McCall MB, Verheijen K, Kullberg BJ, van der Ven AJ, Van der Meer JW, Netea MG. Functional consequences of toll-like receptor 4 polymorphisms. Mol Med. 2008;14:346-352. doi: 10.2119/2007-00135. Ferwerda.
13. O'Neill LA, Bryant CE, Doyle SL. Therapeutic targeting of Toll-like receptors for infectious and inflammatory diseases and cancer. Pharmacol Rev. 2009;61:177-197. doi: 10.1124/pr.109.001073.
14. Werner M, Topp R, Wimmer K, Richter K, Bischof W, Wjst M, Heinrich J. TLR4 gene variants modify endotoxin effects on asthma. J Allergy Clin Immunol. 2003;112:323-330.
15. Cook DN, Pisetsky DS, Schwartz DA. Toll-like receptors in the pathogenesis of human disease. Nat Immunol. 2004;5:975-979. doi: 10.1038/ ni1116.
16. Van Cromphaut SJ, Vanhorebeek I, Van den Berghe G. Glucose metabolism and insulin resistance in sepsis. Curr Pharm Des. 2008;14:1887-1899.
17. Fernández-Real JM, López-Bermejo A, Vendrell J, Ferri MJ, Recasens M, Ricart W. Burden of infection and insulin resistance in healthy middle-aged men. Diabetes Care. 2006;29:1058-1064. doi: 10.2337/diacare.2951058.
18. Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest. 2006;116:3015-3025. doi: 10.1172/JCI28898.
19. Michelsen KS, Wong MH, Shah PK, Zhang W, Yano J, Doherty TM, Akira S, Rajavashisth TB, Arditi M. Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci U S A. 2004;101:10679-10684. doi: 10.1073/pnas.0403249101.
20. Tsukumo DM, Carvalho-Filho MA, Carvalheira JB, Prada PO, Hirabara SM, Schenka AA, Araújo EP, Vassallo J, Curi R, Velloso LA, Saad MJ. Loss-of-function mutation in Toll-like receptor 4 prevents diet-induced obesity and insulin resistance. Diabetes. 2007;56:1986-1998. doi: 10.2337/db06-1595.
21. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest. 2006;116:1793-1801. doi: 10.1172/JCI29069.
22. Shoelson SE, Lee J, Yuan M. Inflammation and the IKK beta/I kappa B/NF-kappa B axis in obesity- and diet-induced insulin resistance. Int J Obes Relat Metab Disord. 2003;27(suppl 3):S49-S52. doi: 10.1038/ sj.ijo.0802501.
23. Frantz S, Ertl G, Bauersachs J. Mechanisms of disease: toll-like receptors in cardiovascular disease. Nat Clin Pract Cardiovasc Med. 2007;4:444-454. doi: 10.1038/ncpcardio0938.
24. Suffredini AF, Fromm RE, Parker MM, Brenner M, Kovacs JA, Wesley RA, Parrillo JE. The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med. 1989;321:280-287. doi: 10.1056/NEJM198908033210503.
25. Elin RJ, Wolff SM. Biology of endotoxin. Annu Rev Med. 1976;27:127-141. doi: 10.1146/annurev.me.27.020176.001015.
26. Michie HR, Spriggs DR, Manogue KR, Sherman ML, Revhaug A, O'Dwyer ST, Arthur K, Dinarello CA, Cerami A, Wolff SM. Tumor necrosis factor and endotoxin induce similar metabolic responses in human beings. Surgery. 1988;104:280-286.
27. Deitch EA. Animal models of sepsis and shock: a review and lessons learned. Shock. 1998;9:1-11.
28. O'Reilly M, Newcomb DE, Remick D. Endotoxin, sepsis, and the primrose path. Shock. 1999;12:411-420.
29. Martich GD, Boujoukos AJ, Suffredini AF. Response of man to endotoxin. Immunobiology. 1993;187:403-416. doi: 10.1016/ S0171-2985(11)80353-0.
30. Ellrodt AG, Riedinger MS, Kimchi A, Berman DS, Maddahi J, Swan HJ, Murata GH. Left ventricular performance in septic shock: reversible segmental and global abnormalities. Am Heart J. 1985;110:402-409.
31. Parker MM, Suffredini AF, Natanson C, Ognibene FP, Shelhamer JH, Parrillo JE. Responses of left ventricular function in survivors and nonsurvivors of septic shock. J Crit Care. 1989;4:19-25.
32. Parker MM, Shelhamer JH, Bacharach SL, Green MV, Natanson C, Frederick TM, Damske BA, Parrillo JE. Profound but reversible myocardial depression in patients with septic shock. Ann Intern Med. 1984;100:483-490.
33. Landesberg G, Gilon D, Meroz Y, Georgieva M, Levin PD, Goodman S, Avidan A, Beeri R, Weissman C, Jaffe AS, Sprung CL. Diastolic dysfunction and mortality in severe sepsis and septic shock. Eur Heart J. 2012;33:895-903. doi: 10.1093/eurheartj/ehr351.
34. Calvano SE, Coyle SM. Experimental human endotoxemia: a model of the systemic inflammatory response syndrome? Surg Infect (Larchmt). 2012;13:293-299. doi: 10.1089/sur.2012.155.
35. Remick DG, Ward PA. Evaluation of endotoxin models for the study of sepsis. Shock. 2005;24(suppl 1):7-11.
36. Mehta NN, Heffron SP, Patel PN, Ferguson J, Shah RD, Hinkle CC, Krishnamoorthy P, Shah R, Tabita-Martinez J, Terembula K, Master SR, Rickels MR, Reilly MP. A human model of inflammatory cardio-metabolic dysfunction; a double blind placebo-controlled crossover trial. J Transl Med. 2012;10:124. doi: 10.1186/1479-5876-10-124.
37. Shah R, Lu Y, Hinkle CC, McGillicuddy FC, Kim R, Hannenhalli S, Cappola TP, Heffron S, Wang X, Mehta NN, Putt M, Reilly MP. Gene profiling of human adipose tissue during evoked inflammation in vivo. Diabetes. 2009;58:2211-2219. doi: 10.2337/db09-0256.
38. Coyle SM, Calvano SE, Lowry SF. Gender influences in vivo human responses to endotoxin. Shock. 2006;26:538-543. doi: 10.1097/01. shk.0000232589.39001.4d.
39. Elin RJ, Wolff SM, McAdam KP, Chedid L, Audibert F, Bernard C, Oberling F. Properties of reference Escherichia coli endotoxin and its phthalylated derivative in humans. J Infect Dis. 1981;144:329-336.
40. Starkie R, Ostrowski SR, Jauffred S, Febbraio M, Pedersen BK. Exercise and IL-6 infusion inhibit endotoxin-induced TNF-alpha production in humans. FASEB J. 2003;17:884-886. doi: 10.1096/fj.02-0670fje.
41. Taudorf S, Krabbe KS, Berg RM, Pedersen BK, Møller K. Human models of low-grade inflammation: bolus versus continuous infusion of endotoxin. Clin Vaccine Immunol. 2007;14:250-255. doi: 10.1128/CVI.00380-06.
42. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest. 1995;95:2409-2415. doi: 10.1172/JCI117936.
43. Winkler G, Salamon F, Harmos G, Salamon D, Speer G, Szekeres O, Hajós P, Kovács M, Simon K, Cseh K. Elevated serum tumor necrosis factor-alpha concentrations and bioactivity in Type 2 diabetics and patients with android type obesity. Diabetes Res Clin Pract. 1998;42:169-174.
44. Fain JN. Release of interleukins and other inflammatory cytokines by human adipose tissue is enhanced in obesity and primarily due to the nonfat cells. Vitam Horm. 2006;74:443-477. doi: 10.1016/ S0083-6729(06)74018-3.
45. Mullington J, Korth C, Hermann DM, Orth A, Galanos C, Holsboer F, Pollmächer T. Dose-dependent effects of endotoxin on human sleep. Am J Physiol Regul Integr Comp Physiol. 2000;278:R947-R955.
46. Piya MK, Harte AL, McTernan PG. Metabolic endotoxaemia: is it more than just a gut feeling? Curr Opin Lipidol. 2013;24:78-85. doi: 10.1097/ MOL.0b013e32835b4431.
47. Shen J, Obin MS, Zhao L. The gut microbiota, obesity and insulin resistance. Mol Aspects Med. 2013;34:39-58. doi: 10.1016/j.mam.2012.11.001.
48. Harte AL, Varma MC, Tripathi G, McGee KC, Al-Daghri NM, Al-Attas OS, Sabico S, O'Hare JP, Ceriello A, Saravanan P, Kumar S, McTernan PG. High fat intake leads to acute postprandial exposure to circulating endotoxin in type 2 diabetic subjects. Diabetes Care. 2012;35:375-382. doi: 10.2337/dc11-1593.
49. Amar J, Burcelin R, Ruidavets JB, Cani PD, Fauvel J, Alessi MC, Chamontin B, Ferriéres J. Energy intake is associated with endotoxemia in apparently healthy men. Am J Clin Nutr. 2008;87:1219-1223.
50. Brun P, Castagliuolo I, Di Leo V, Buda A, Pinzani M, Palù G, Martines D. Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis. Am J Physiol Gastrointest Liver Physiol. 2007;292:G518-G525. doi: 10.1152/ajpgi.00024.2006.
51. Cani PD, Amar J, Iglesias MA, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56:1761-1772. doi: 10.2337/ db06-1491.
52. Koeth RA, Wang Z, Levison BS, et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med. 2013;19:576-585. doi: 10.1038/nm.3145.
53. Tang WH, Wang Z, Levison BS, Koeth RA, Britt EB, Fu X, Wu Y, Hazen SL. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med. 2013;368:1575-1584. doi: 10.1056/ NEJMoa1109400.
54. Wu GD, Chen J, Hoffmann C, et al. Linking long-term dietary patterns with gut microbial enterotypes. Science. 2011;334:105-108. doi: 10.1126/ science.1208344.
55. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature. 2006;444:1022-1023. doi: 10.1038/4441022a.
56. De Bandt JP, Waligora-Dupriet AJ, Butel MJ. Intestinal microbiota in inflammation and insulin resistance: relevance to humans. Curr Opin Clin Nutr Metab Care. 2011;14:334-340. doi: 10.1097/ MCO.0b013e328347924a.
57. Cani PD, Osto M, Geurts L, Everard A. Involvement of gut microbiota in the development of low-grade inflammation and type 2 diabetes associated with obesity. Gut Microbes. 2012;3:279-288. doi: 10.4161/gmic.19625.
58. Carvalho BM, Guadagnini D, Tsukumo DM, Schenka AA, Latuf-Filho P, Vassallo J, Dias JC, Kubota LT, Carvalheira JB, Saad MJ. Modulation of gut microbiota by antibiotics improves insulin signalling in high-fat fed mice. Diabetologia. 2012;55:2823-2834. doi: 10.1007/s00125-012-2648-4.
59. Murphy EF, Cotter PD, Hogan A, O'Sullivan O, Joyce A, Fouhy F, Clarke SF, Marques TM, O'Toole PW, Stanton C, Quigley EM, Daly C, Ross PR, O'Doherty RM, Shanahan F. Divergent metabolic outcomes arising from targeted manipulation of the gut microbiota in diet-induced obesity. Gut. 2013;62:220-226. doi: 10.1136/gutjnl-2011-300705.
60. Koren O, Spor A, Felin J, Fåk F, Stombaugh J, Tremaroli V, Behre CJ, Knight R, Fagerberg B, Ley RE, Bäckhed F. Human oral, gut, and plaque microbiota in patients with atherosclerosis. Proc Natl Acad Sci U S A. 2011;108(suppl 1):4592-4598. doi: 10.1073/pnas.1011383107.
61. Amar J, Serino M, Lange C, et al; D.E.S.I.R. Study Group. Involvement of tissue bacteria in the onset of diabetes in humans: evidence for a concept. Diabetologia. 2011;54:3055-3061. doi: 10.1007/s00125-011-2329-8.
62. Agwunobi AO, Reid C, Maycock P, Little RA, Carlson GL. Insulin resistance and substrate utilization in human endotoxemia. J Clin Endocrinol Metab. 2000;85:3770-3778. doi: 10.1210/jcem.85.10.6914.
63. Mehta NN, McGillicuddy FC, Anderson PD, Hinkle CC, Shah R, Pruscino L, Tabita-Martinez J, Sellers KF, Rickels MR, Reilly MP. Experimental endotoxemia induces adipose inflammation and insulin resistance in humans. Diabetes. 2010;59:172-181. doi: 10.2337/db09-0367.
64. Ferguson JF, Patel PN, Shah RY, Mulvey CK, Gadi R, Nijjar PS, Usman HM, Mehta NN, Shah R, Master SR, Propert KJ, Reilly MP. Race and gender variation in response to evoked inflammation. J Transl Med. 2013;11:63. doi: 10.1186/1479-5876-11-63.
65. Weisberg SP, Hunter D, Huber R, Lemieux J, Slaymaker S, Vaddi K, Charo I, Leibel RL, Ferrante AW Jr. CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J Clin Invest. 2006;116:115-124. doi: 10.1172/JCI24335.
66. Anderson PD, Mehta NN, Wolfe ML, Hinkle CC, Pruscino L, Comiskey LL, Tabita-Martinez J, Sellers KF, Rickels MR, Ahima RS, Reilly MP. Innate immunity modulates adipokines in humans. J Clin Endocrinol Metab. 2007;92:2272-2279. doi: 10.1210/jc.2006-2545.
67. Levels JH, Pajkrt D, Schultz M, Hoek FJ, van Tol A, Meijers JC, van Deventer SJ. Alterations in lipoprotein homeostasis during human experimental endotoxemia and clinical sepsis. Biochim Biophys Acta. 2007;1771:1429-1438. doi: 10.1016/j.bbalip.2007.10.001.
68. Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab. 1992;74:1045-1052. doi: 10.1210/ jcem.74.5.1373735.
69. van der Westhuyzen DR, de Beer FC, Webb NR. HDL cholesterol transport during inflammation. Curr Opin Lipidol. 2007;18:147-151. doi: 10.1097/MOL.0b013e328051b4fe.
70. Khovidhunkit W, Kim MS, Memon RA, Shigenaga JK, Moser AH, Feingold KR, Grunfeld C. Thematic review series: the pathogenesis of atherosclerosis. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res. 2004;45:1169-1196. doi: 10.1194/jlr.R300019-JLR200.
71. Hudgins LC, Parker TS, Levine DM, Gordon BR, Saal SD, Jiang XC, Seidman CE, Tremaroli JD, Lai J, Rubin AL. A single intravenous dose of endotoxin rapidly alters serum lipoproteins and lipid transfer proteins in normal volunteers. J Lipid Res. 2003;44:1489-1498. doi: 10.1194/jlr.M200440-JLR200.
72. Wang X, Rader DJ. Molecular regulation of macrophage reverse cholesterol transport. Curr Opin Cardiol. 2007;22:368-372. doi: 10.1097/ HCO.0b013e3281ec5113.
73. McGillicuddy FC, de la Llera Moya M, Hinkle CC, Joshi MR, Chiquoine EH, Billheimer JT, Rothblat GH, Reilly MP. Inflammation impairs reverse cholesterol transport in vivo. Circulation. 2009;119:1135-1145. doi: 10.1161/CIRCULATIONAHA.108.810721.
74. de la Llera Moya M, McGillicuddy FC, Hinkle CC, Byrne M, Joshi MR, Nguyen V, Tabita-Martinez J, Wolfe ML, Badellino K, Pruscino L, Mehta NN, Asztalos BF, Reilly MP. Inflammation modulates human hdl composition and function in vivo. Atherosclerosis. 2012;222:390-394.
75. Badellino KO, Wolfe ML, Reilly MP, Rader DJ. Endothelial lipase is increased in vivo by inflammation in humans. Circulation. 2008;117:678-685. doi: 10.1161/CIRCULATIONAHA.107.707349.
76. Cavallero E, Brites F, Delfly B, Nicolaïew N, Decossin C, De Geitere C, Fruchart JC, Wikinski R, Jacotot B, Castro G. Abnormal reverse cholesterol transport in controlled type II diabetic patients. Studies on fasting and postprandial LpA-I particles. Arterioscler Thromb Vasc Biol. 1995;15:2130-2135.
77. Mooradian AD, Haas MJ, Wehmeier KR, Wong NC. Obesity-related changes in high-density lipoprotein metabolism. Obesity (Silver Spring). 2008;16:1152-1160. doi: 10.1038/oby.2008.202.
78. Holzer M, Wolf P, Curcic S, Birner-Gruenberger R, Weger W, Inzinger M, El-Gamal D, Wadsack C, Heinemann A, Marsche G. Psoriasis alters HDL composition and cholesterol efflux capacity. J Lipid Res. 2012;53:1618-1624. doi: 10.1194/jlr.M027367.
79. McMahon M, Grossman J, FitzGerald J, Dahlin-Lee E, Wallace DJ, Thong BY, Badsha H, Kalunian K, Charles C, Navab M, Fogelman AM, Hahn BH. Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum. 2006;54:2541-2549. doi: 10.1002/art.21976.
80. Van Lenten BJ, Hama SY, de Beer FC, Stafforini DM, McIntyre TM, Prescott SM, La Du BN, Fogelman AM, Navab M. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest. 1995;96:2758-2767. doi: 10.1172/JCI118345.
81. Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, French BC, Phillips JA, Mucksavage ML, Wilensky RL, Mohler ER, Rothblat GH, Rader DJ. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med. 2011;364:127-135. doi: 10.1056/NEJMoa1001689.
82. van Eijk LT, Dorresteijn MJ, Smits P, van der Hoeven JG, Netea MG, Pickkers P. Gender differences in the innate immune response and vascular reactivity following the administration of endotoxin to human volunteers. Crit Care Med. 2007;35:1464-1469. doi: 10.1097/01. CCM.0000266534.14262.E8.
83. Alamili M, Bendtzen K, Lykkesfeldt J, Rosenberg J, Gögenur I. Pronounced inflammatory response to endotoxaemia during nighttime: a randomised cross-over trial. PLoS One. 2014;9:e87413. doi: 10.1371/ journal.pone.0087413.
84. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, Gallimore JR, Pepys MB. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ. 2000;321:199-204.
85. Pradhan AD, Manson JE, Rossouw JE, Siscovick DS, Mouton CP, Rifai N, Wallace RB, Jackson RD, Pettinger MB, Ridker PM. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study. JAMA. 2002;288:980-987.
86. Krug S, Kastenmüller G, Stückler F, et al. The dynamic range of the human metabolome revealed by challenges. FASEB J. 2012;26:2607-2619. doi: 10.1096/fj.11-198093.
87. van Ommen B, van der Greef J, Ordovas JM, Daniel H. Phenotypic flexibility as key factor in the human nutrition and health relationship. Genes Nutr. 2014;9:423. doi: 10.1007/s12263-014-0423-5.
88. Paalani M, Lee JW, Haddad E, Tonstad S. Determinants of inflammatory markers in a bi-ethnic population. Ethn Dis. 2011;21:142-149.
89. Steffen BT, Steffen LM, Tracy R, Siscovick D, Jacobs D, Liu K, He K, Hanson NQ, Nettleton JA, Tsai MY. Ethnicity, plasma phospholipid fatty acid composition and inflammatory/endothelial activation biomarkers in the Multi-Ethnic Study of Atherosclerosis (MESA). Eur J Clin Nutr. 2012;66:600-605. doi: 10.1038/ejcn.2011.215.
90. Khera A, McGuire DK, Murphy SA, Stanek HG, Das SR, Vongpatanasin W, Wians FH Jr, Grundy SM, de Lemos JA. Race and gender differences in C-reactive protein levels. J Am Coll Cardiol. 2005;46:464-469. doi: 10.1016/j.jacc.2005.04.051.
91. Ferguson JF, Meyer NJ, Qu L, Xue C, Liu Y, DerOhannessian SL, Rushefski M, Paschos GK, Tang S, Schadt EE, Li M, Christie JD, Reilly MP. Integrative genomics identifies 7p11.2 as a novel locus for fever and clinical stress response in humans [published online ahead of print November 20, 2014]. Hum Mol Genet. doi: 10.1093/hmg/ddu589.
92. Franco LM, Bucasas KL, Wells JM, Niño D, Wang X, Zapata GE, Arden N, Renwick A, Yu P, Quarles JM, Bray MS, Couch RB, Belmont JW, Shaw CA. Integrative genomic analysis of the human immune response to influenza vaccination. Elife. 2013;2:e00299. doi: 10.7554/eLife.00299.
93. Daly AK. Genome-wide association studies in pharmacogenomics. Nat Rev Genet. 2010;11:241-246. doi: 10.1038/nrg2751.
94. Dillon MA, Harris B, Hernandez ML, Zou B, Reed W, Bromberg PA, Devlin RB, Diaz-Sanchez D, Kleeberger S, Zhou H, Lay JC, Alexis NE, Peden DB. Enhancement of systemic and sputum granulocyte response to inhaled endotoxin in people with the GSTM1 null genotype. Occup Environ Med. 2011;68:783-785. doi: 10.1136/oem.2010.061747.
95. Chen R, Mias GI, Li-Pook-Than J, et al. Personal omics profiling reveals dynamic molecular and medical phenotypes. Cell. 2012;148:1293-1307. doi: 10.1016/j.cell.2012.02.009.
96. Munford RS. Murine responses to endotoxin: another dirty little secret? J Infect Dis. 2010;201:175-177. doi: 10.1086/649558.
97. Novoa B, Bowman TV, Zon L, Figueras A. LPS response and tolerance in the zebrafish (Danio rerio). Fish Shellfish Immunol. 2009;26:326-331. doi: 10.1016/j.fsi.2008.12.004.
98. Seok J, Warren HS, Cuenca AG, et al; Inflammation and Host Response to Injury, Large Scale Collaborative Research Program. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci U S A. 2013;110:3507-3512. doi: 10.1073/pnas.1222878110.
99. Takao K, Miyakawa T. Genomic responses in mouse models greatly mimic human inflammatory diseases [published online ahead of print August 4, 2014]. Proc Natl Acad Sci U S A. doi: 10.1073/pnas.1401965111.
100. Fairfax BP, Humburg P, Makino S, Naranbhai V, Wong D, Lau E, Jostins L, Plant K, Andrews R, McGee C, Knight JC. Innate immune activity conditions the effect of regulatory variants upon monocyte gene expression. Science. 2014;343:1246949. doi: 10.1126/science.1246949.
101. Lee MN, Ye C, Villani AC, et al. Common genetic variants modulate pathogen-sensing responses in human dendritic cells. Science. 2014;343:1246980. doi: 10.1126/science.1246980.
102. Kox M, de Kleijn S, Pompe JC, Ramakers BP, Netea MG, van der Hoeven JG, Hoedemaekers CW, Pickkers P. Differential ex vivo and in vivo endotoxin tolerance kinetics following human endotoxemia. Crit Care Med. 2011;39:1866-1870. doi: 10.1097/CCM.0b013e3182190d5d.
103. Arbour NC, Lorenz E, Schutte BC, Zabner J, Kline JN, Jones M, Frees K, Watt JL, Schwartz DA. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet. 2000;25:187-191. doi: 10.1038/76048.
104. Fijen JW, Tulleken JE, Hepkema BG, van der Werf TS, Ligtenberg JJ, Zijlstra JG. The influence of tumor necrosis factor-alpha and interleukin-10 gene promoter polymorphism on the inflammatory response in experimental human endotoxemia. Clin Infect Dis. 2001;33:1601-1603. doi: 10.1086/323197.
105. Endler G, Marsik C, Joukhadar C, Marculescu R, Mayr F, Mannhalter C, Wagner OF, Jilma B. The interleukin-6 G(-174)C promoter polymorphism does not determine plasma interleukin-6 concentrations in experimental endotoxemia in humans. Clin Chem. 2004;50:195-200. doi: 10.1373/clinchem.2003.022459.
106. Calvano SE, Xiao W, Richards DR, et al; Inflamm and Host Response to Injury Large Scale Collab. Res. Program. A network-based analysis of systemic inflammation in humans. Nature. 2005;437:1032-1037. doi: 10.1038/nature03985.
107. Liu Y, Ferguson JF, Xue C, Ballantyne RL, Silverman IM, Gosai SJ, Serfecz J, Morley MP, Gregory BD, Li M, Reilly MP. Tissue-specific RNA-Seq in human evoked inflammation identifies blood and adipose LincRNA signatures of cardiometabolic diseases. Arterioscler Thromb Vasc Biol. 2014;34:902-912. doi: 10.1161/ATVBAHA.113.303123.
108. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, Leeb B, Breedveld FC, Macfarlane JD, Bijl H. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet. 1994;344:1105-1110.
109. van Dullemen HM, van Deventer SJ, Hommes DW, Bijl HA, Jansen J, Tytgat GN, Woody J. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology. 1995;109:129-135.
110. Gorman JD, Sack KE, Davis JC Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med. 2002;346:1349-1356. doi: 10.1056/NEJMoa012664.
111. Burns CM, Wortmann RL. Gout therapeutics: new drugs for an old disease. Lancet. 2011;377:165-177. doi: 10.1016/S0140-6736(10)60665-4.
112. Bunnell E, Lynn M, Habet K, Neumann A, Perdomo CA, Friedhoff LT, Rogers SL, Parrillo JE. A lipid A analog, E5531, blocks the endotoxin response in human volunteers with experimental endotoxemia. Crit Care Med. 2000;28:2713-2720.
113. Kumar A, Bunnell E, Lynn M, Anel R, Habet K, Neumann A, Parrillo JE. Experimental human endotoxemia is associated with depression of load-independent contractility indices: prevention by the lipid a analogue E5531. Chest. 2004;126:860-867. doi: 10.1378/chest.126.3.860.
114. Van Zee KJ, Coyle SM, Calvano SE, Oldenburg HS, Stiles DM, Pribble J, Catalano M, Moldawer LL, Lowry SF. Influence of IL-1 receptor blockade on the human response to endotoxemia. J Immunol. 1995;154:1499-1507.
115. Granowitz EV, Porat R, Mier JW, Orencole SF, Callahan MV, Cannon JG, Lynch EA, Ye K, Poutsiaka DD, Vannier E. Hematologic and immunomodulatory effects of an interleukin-1 receptor antagonist coinfusion during low-dose endotoxemia in healthy humans. Blood. 1993;82:2985-2990.
116. Pajkrt D, Camoglio L, Tiel-van Buul MC, de Bruin K, Cutler DL, Affrime MB, Rikken G, van der Poll T, ten Cate JW, van Deventer SJ. Attenuation of proinflammatory response by recombinant human IL-10 in human endotoxemia: effect of timing of recombinant human IL-10 administration. J Immunol. 1997;158:3971-3977.
117. Olszyna DP, Pajkrt D, Lauw FN, van Deventer SJ, van Der Poll T. Interleukin 10 inhibits the release of CC chemokines during human endotoxemia. J Infect Dis. 2000;181:613-620. doi: 10.1086/315275.
118. Suffredini AF, Reda D, Banks SM, Tropea M, Agosti JM, Miller R. Effects of recombinant dimeric TNF receptor on human inflammatory responses following intravenous endotoxin administration. J Immunol. 1995;155:5038-5045.
119. van der Poll T, Coyle SM, Levi M, Jansen PM, Dentener M, Barbosa K, Buurman WA, Hack CE, ten Cate JW, Agosti JM, Lowry SF. Effect of a recombinant dimeric tumor necrosis factor receptor on inflammatory responses to intravenous endotoxin in normal humans. Blood. 1997;89:3727-3734.
120. Shannon E, Noveck R, Sandoval F, Kamath B, Kearney M. Thalidomide suppressed interleukin-6 but not tumor necrosis factor-alpha in volunteers with experimental endotoxemia. Transl Res. 2007;150:275-280. doi: 10.1016/j.trsl.2007.05.003.
121. de Kruif MD, Lemaire LC, Giebelen IA, Groot AP, Pater JM, van den Pangaart PS, Elliott PJ, van der Poll T. Effects of prednisolone on the systemic release of mediators of cell-mediated cytotoxicity during human endotoxemia. Shock. 2008;29:458-461. doi: 10.1097/ shk.0b013e3181598a6a.
122. de Kruif MD, Lemaire LC, Giebelen IA, van Zoelen MA, Pater JM, van den Pangaart PS, Groot AP, de Vos AF, Elliott PJ, Meijers JC, Levi M, van der Poll T. Prednisolone dose-dependently influences inflammation and coagulation during human endotoxemia. J Immunol. 2007;178:1845-1851.
123. Lemaire LC, de Kruif MD, Giebelen IA, Levi M, van der Poll T, Heesen M. Dobutamine does not influence inflammatory pathways during human endotoxemia. Crit Care Med. 2006;34:1365-1371. doi: 10.1097/01.CCM.0000215514.96888.E3.
124. Mulvey CK, Ferguson JF, Tabita-Martinez J, Kong S, Shah RY, Patel PN, Master SR, Usman MH, Propert KJ, Shah R, Mehta NN, Reilly MP. Peroxisome proliferator-activated receptor-α agonism with fenofibrate does not suppress inflammatory responses to evoked endotoxemia. J Am Heart Assoc. 2012;1:e002923. doi: 10.1161/JAHA.112.002923.
125. Ferguson JF, Mulvey CK, Patel PN, et al. Omega-3 PUFA supplementation and the response to evoked endotoxemia in healthy volunteers. Mol Nutr Food Res. 2014;58:601-613. doi: 10.1002/mnfr.201300368.
126. Pluess TT, Hayoz D, Berger MM, Tappy L, Revelly JP, Michaeli B, Carpentier YA, Chioléro RL. Intravenous fish oil blunts the physiological response to endotoxin in healthy subjects. Intensive Care Med. 2007;33:789-797. doi: 10.1007/s00134-007-0591-5.
127. Michaeli B, Berger MM, Revelly JP, Tappy L, Chioléro R. Effects of fish oil on the neuro-endocrine responses to an endotoxin challenge in healthy volunteers. Clin Nutr. 2007;26:70-77. doi: 10.1016/j. clnu.2006.06.001.
128. Ferguson JF, Ryan MF, Gibney ER, Brennan L, Roche HM, Reilly MP. Dietary isoflavone intake is associated with evoked responses to inflammatory cardiometabolic stimuli and improved glucose homeostasis in healthy volunteers. Nutr Metab Cardiovasc Dis. 2014;24:996-1003. doi: 10.1016/j.numecd.2014.03.010.
129. Meyer NJ, Ferguson JF, Feng R, Wang F, Patel PN, Li M, Xue C, Qu L, Liu Y, Boyd JH, Russell JA, Christie JD, Walley KR, Reilly MP. A functional synonymous coding variant in the IL1RN gene is associated with survival in septic shock. Am J Respir Crit Care Med. 2014;190:656-664. doi: 10.1164/rccm.201403-0586OC.
130. Rella JM, Jilma B, Fabry A, Kaynar AM, Mayr FB. MMP-8 genotypes influence the inflammatory response in human endotoxemia. Inflammation. 2014;37:451-456. doi: 10.1007/s10753-013-9758-0.
131. Kovar FM, Marsik C, Jilma B, Mannhalter C, Quehenberger P, Handler S, Wagner OF, Endler G. The fibrinogen -148 C/T polymorphism influences inflammatory response in experimental endotoxemia in vivo. Thromb Res. 2007;120:727-731. doi: 10.1016/j.thromres.2006.12.007.
132. Marsik C, Sunder-Plassmann R, Jilma B, Kovar FM, Mannhalter C, Wagner O, Rumpold H, Endler G. The C-reactive protein (+)1444C/T alteration modulates the inflammation and coagulation response in human endotoxemia. Clin Chem. 2006;52:1952-1957. doi: 10.1373/ clinchem.2006.069823.
133. Marsik C, Jilma B, Joukhadar C, Mannhalter C, Wagner O, Endler G. The Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms influence the late inflammatory response in human endotoxemia. Clin Chem. 2005;51:2178-2180. doi: 10.1373/clinchem.2005.051649.
134. Kovar FM, Marsik C, Cvitko T, Wagner OF, Jilma B, Endler G. The tumor necrosis factor alpha -308 G/A polymorphism does not influence inflammation and coagulation response in human endotoxemia. Shock. 2007;27:238-241. doi: 10.1097/01.shk.0000239768.64786.3a.
135. Draisma A, Pickkers P, Bouw MP, van der Hoeven JG. Development of endotoxin tolerance in humans in vivo. Crit Care Med. 2009;37:1261-1267. doi: 10.1097/CCM.0b013e31819c3c67.
136. Draisma A, Bemelmans R, van der Hoeven JG, Spronk P, Pickkers P. Microcirculation and vascular reactivity during endotoxemia and endotoxin tolerance in humans. Shock. 2009;31:581-585. doi: 10.1097/ SHK.0b013e318193e187.
137. Draisma A, de Goeij M, Wouters CW, Riksen NP, Oyen WJ, Rongen GA, Boerman OC, van Deuren M, van der Hoeven JG, Pickkers P. Endotoxin tolerance does not limit mild ischemia-reperfusion injury in humans in vivo. Innate Immun. 2009;15:360-367. doi: 10.1177/1753425909105548.
138. Leentjens J, Kox M, Koch RM, Preijers F, Joosten LA, van der Hoeven JG, Netea MG, Pickkers P. Reversal of immunoparalysis in humans in vivo: a double-blind, placebo-controlled, randomized pilot study. Am J Respir Crit Care Med. 2012;186:838-845. doi: 10.1164/ rccm.201204-0645OC.
139. Preas HL II, Reda D, Tropea M, Vandivier RW, Banks SM, Agosti JM, Suffredini AF. Effects of recombinant soluble type I interleukin-1 receptor on human inflammatory responses to endotoxin. Blood. 1996;88:2465-2472.